Natera (NASDAQ:NTRA) Price Target Raised to $250.00

Natera (NASDAQ:NTRA) had its target price upped by Canaccord Genuity Group from $200.00 to $250.00 in a report released on Friday,Benzinga reports. The firm currently has a buy rating on the medical research company’s stock.

A number of other equities research analysts have also recently issued reports on NTRA. BTIG Research raised their target price on Natera from $210.00 to $230.00 and gave the company a “buy” rating in a research note on Friday. Morgan Stanley reaffirmed an “overweight” rating and issued a $195.00 price objective on shares of Natera in a report on Sunday, August 10th. JPMorgan Chase & Co. lifted their price objective on shares of Natera from $210.00 to $240.00 and gave the company an “overweight” rating in a research report on Friday. BNP Paribas Exane raised shares of Natera from an “underperform” rating to a “neutral” rating and set a $172.00 target price for the company in a research note on Monday, October 27th. Finally, Piper Sandler restated an “overweight” rating and issued a $220.00 price target (up previously from $210.00) on shares of Natera in a research note on Monday, August 11th. Seventeen investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $206.74.

Natera Stock Up 0.5%

Shares of NTRA stock opened at $199.57 on Friday. The business has a 50 day moving average of $177.75 and a two-hundred day moving average of $163.91. Natera has a 52 week low of $125.38 and a 52 week high of $203.23. The company has a market cap of $27.39 billion, a P/E ratio of -87.15 and a beta of 1.74.

Natera (NASDAQ:NTRA) last announced its quarterly earnings results on Thursday, November 6th. The medical research company reported ($0.64) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.25). Natera had a negative return on equity of 25.20% and a negative net margin of 14.61%.The company had revenue of $592.18 million during the quarter, compared to the consensus estimate of $514.55 million. During the same period last year, the business posted ($0.26) EPS. The company’s revenue for the quarter was up 34.7% on a year-over-year basis. Natera has set its FY 2025 guidance at EPS. Analysts expect that Natera will post -1.49 EPS for the current fiscal year.

Insider Activity at Natera

In other news, CFO Michael Burkes Brophy sold 2,491 shares of the stock in a transaction that occurred on Tuesday, September 30th. The shares were sold at an average price of $162.05, for a total value of $403,666.55. Following the completion of the transaction, the chief financial officer directly owned 69,189 shares in the company, valued at $11,212,077.45. This trade represents a 3.48% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Solomon Moshkevich sold 3,000 shares of the firm’s stock in a transaction that occurred on Wednesday, October 1st. The shares were sold at an average price of $159.99, for a total transaction of $479,970.00. Following the transaction, the insider owned 117,559 shares in the company, valued at $18,808,264.41. This represents a 2.49% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 224,889 shares of company stock worth $43,232,062 in the last 90 days. Corporate insiders own 5.63% of the company’s stock.

Hedge Funds Weigh In On Natera

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Guided Capital Wealth Management LLC raised its stake in shares of Natera by 0.5% in the 2nd quarter. Guided Capital Wealth Management LLC now owns 13,135 shares of the medical research company’s stock worth $2,219,000 after buying an additional 66 shares in the last quarter. Main Management ETF Advisors LLC grew its holdings in Natera by 1.7% during the second quarter. Main Management ETF Advisors LLC now owns 4,398 shares of the medical research company’s stock worth $743,000 after acquiring an additional 72 shares during the period. Yousif Capital Management LLC raised its position in Natera by 4.5% in the third quarter. Yousif Capital Management LLC now owns 1,682 shares of the medical research company’s stock worth $271,000 after acquiring an additional 72 shares in the last quarter. Wedmont Private Capital lifted its holdings in Natera by 4.9% in the 2nd quarter. Wedmont Private Capital now owns 1,580 shares of the medical research company’s stock valued at $256,000 after acquiring an additional 74 shares during the last quarter. Finally, Gries Financial LLC boosted its position in shares of Natera by 4.0% during the 3rd quarter. Gries Financial LLC now owns 1,904 shares of the medical research company’s stock valued at $306,000 after purchasing an additional 74 shares in the last quarter. 99.90% of the stock is owned by institutional investors.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.